Connect with us

Cannabis News

Grow Up Vancouver sets the tone for 2026 cannabis

Published

on

The start of this cannabis year was marked by the latest edition of the Grow Up conference in Vancouver, which seems to be setting the tone for what to expect from the industry in 2026. Exhibitors and attendees reported that the industry is becoming more measured, operationally focused, and increasingly aware that long-term viability depends on execution rather than wishful thinking. “Grow Up was a very positive experience, with direct and practical conversations with growers and partners. The event created a space for meaningful discussions, focused on current market realities and field-level challenges,” said the BioFloral team.

For Cannatrol, the show highlighted how it has become a post-harvest strategy. “In Grow Up 2026, Cannatrol brings technology that works where few solutions exist, setting new standards for the industry,” said David Sandelman, chief technology officer and company founder. Appearing at the event, along with new Canadian distribution partner Quality Horticulture, Cannatrol used the conference to highlight a once-left-behind process as an increasingly crucial part of every cannabis operation. “We’re here to show conference attendees why your post-harvest system matters even more than the growing process.”

Since cannabis was regulated, many growers have focused more on maximizing fat space, relegating drying, curing and all that to a small part of their operation. So it seems that the industry is indicating that the sector is maturing, and the year 2026 is crucial to show this. “Cannatrol sees 2026 as a new phase of maturity for the cannabis industry driven by potential rescheduling and more disciplined business practices focused on operational efficiency.” In such an environment, he added, “quality and consistency are no longer differentiators, but critical drivers for producing top-notch craftsmanship and achieving successful business growth.”

The very tone of the event was in favor of this assessment. David described Grow Up as “a very positive experience, with direct and practical conversations with growers and partners”, noting that “the event created a space for meaningful discussions based on market realities and field-level challenges”. He also saw a clear change in behavior among producers. The same sentiment is echoed by the BioFloral team, who noticed that attendees were more interested in practical solutions than the latest shiny toy. “We’ve noticed an increasing focus on efficiency, consistency and long-term profitability. Growers seem less driven by novelty and more interested in stable, proven solutions.”

Exhibitors for the first time, such as the Fraser Valley Organic Producers Association, are joining the world of cannabis with a new benchmark in organic cannabis cultivation. “We really enjoyed being part of the Grow Up show this year. We received a great response from the attendees, with many expressing an interest in learning more about the organic certification of cannabis. As this was our first time attending the conference, we were very pleased with the diversity of industry players in attendance. It was particularly interesting to learn more about the research that some growers are doing into the medical use of cannabis.

Similar pragmatism emerged from brand-focused exhibitors. The Pure Sunfarms and Super Toast teams reported that Grow Up Vancouver provided a valuable opportunity to strengthen retail relationships and strengthen their presence in British Columbia. “Grow Up Vancouver was a strong opportunity to share more about our evolving portfolio, strengthen connections with retail partners and their teams, and highlight our deep connection to British Columbia as our home market,” the company said, adding that “the quality of the conversations was high and it was gratifying to see such thoughtful engagement across the industry.”

From the point of view of the market, retailers appear to be more and more selective. “One of the most noticeable changes is the continued push behind convenience-driven categories,” the team noted. “There is a strong demand for products that are easy to understand, easy to use and fit seamlessly into consumer routines, especially formats that prioritize consistency, quality and accessibility.”

For other attendees, Grow Up Vancouver also reinforced a sense of confidence in an industry that continues to grow despite many obstacles. “Grow Up Vancouver was the perfect start to 2026,” says Atiyyah Ferouz, founder of AgCann Consultancy. “There was a renewed energy and positivity that was palpable throughout the event.” This optimism was linked to a growing strategic awareness, especially regarding market diversification. “A big trend, which has been increasing year by year, is the focus on the export market,” continued Atiyyah. “We’ve spoken to a number of producers who have included export readiness as a key part of their 2026 strategy. In many of the conversations we had, producers were still keen to supply the Canadian market, but wanted to make sure their sales weren’t completely dependent on a single market.”

This vision is shaped by an industry that, despite pressure, is not standing still.” The Canadian cannabis industry is in a strong position today,” stated the GrowerIQ team. “Producers continue to benefit from expanded international legalization, global underproduction and the gradual reduction of the gray market. The continued maturation of Canadian and international supply chains has opened up access to markets that were previously difficult for medium and smaller producers to tap into.”

At the same time, challenges remain. “Regulatory complexity, taxation and access to capital continue to impact the industry,” they continued. “Competition from low-cost jurisdictions and domestic producers unloading excess product at discounted prices is keeping prices under pressure. Individual producers continue to face business-specific challenges, while the rapid pace of change in the sector increases these pressures. Those who cannot adapt quickly risk being left behind in this fast-moving market.”

Despite the headwinds, there is cautious confidence. “2026 has the potential to be another challenging but successful year for the Canadian cannabis industry,” they concluded. The seed itself seems to be evolving along with the sector. “Grow Up continues to raise the bar every year,” said the GrowerIQ team. “Grow Up has truly established itself as Canada’s premier cannabis event.”

Overall, the Grow Up conference in Vancouver showed an industry that is recalibrating itself around consistency, efficiency and strategic resilience. Long (?) gone are the days of big announcements and earth-shattering innovations. The sector is preparing for its next tougher phase.

For more information:
grow up
growupconference.com

Cannabis News

Tilray Medical announces commercial launch of medical cannabis in Panama

Published

on

By

Tilray Medical has announced the launch of its first medical cannabis product in Panama, part of the company’s continued global expansion and commitment to improving patient access to pharmaceutical grade cannabinoids worldwide.

Following the successful shipment of Tilray Oral Solution CBD100 from Tilray Medical’s EU-GMP certified production facilities in Portugal through a joint venture with Solana Life Group S. de RL, the Product is to be distributed through Farmacias Arrocha, one of the leading pharmaceutical chains in Panama, where patients will be able to access Tilray Oral Solution CBD with medical prescription100. This is expected to provide patients and healthcare professionals with access to regulated medical cannabis of pharmaceutical quality through established healthcare channels.

Rajnish Ohri, International President, Tilray Brands, said: “At Tilray Medical, we believe that every patient deserves access to safe, consistent, pharmaceutical-grade cannabis products. The launch in Panama reflects our broader vision to expand access to cannabinoid-based medicines around the world. We want pharmacists and patients to help shape the future of responsible access, advance medical education and provide high-quality treatment options that improve lives.”

The launch supports the Panamanian medical cannabis framework established by Law 242 of 2021 and follows important regulatory advances made by the Ministry of Health, including No. 0406 of May 12, 2026. The decision, which established the main conditions for the admission of patients. The Ministry also recently introduced the System for the Identification of Medical Cannabis Users and Authorized Caregivers (SIUCMAA), creating a structured way to authorize medical practitioners and register patients.

Manufactured in Portugal under strict European Union Good Manufacturing Practice (EU-GMP) standards, Tilray Oral Solution CBD100 is intended for use in patients with qualified medical conditions permitted under Panamanian law, where permitted. The products reflect Tilray Medical’s longstanding commitment to pharmaceutical quality, product consistency, patient safety and regulatory compliance.

Tilray Medical’s advanced cultivation and manufacturing facilities in Portugal serve as a strategic global export hub, supplying EU-GMP certified medical cannabis products to regulated markets worldwide. The platform enables Tilray Medical to effectively support growing international demand while maintaining the highest pharmaceutical manufacturing standards across its global operations.

For more information:
Tilray
www.tilray.com

Continue Reading

Cannabis News

Medical Marijuana Is ‘Effective’ In Providing Relief To Patients With Restless Legs Syndrome, Study Shows

Published

on

By

People with restless leg syndrome (RLS) may find “significant” long-term relief with cannabis treatment, according to a new study.

While dopamine agonists have traditionally been the “first-line treatment” for RLS, recent studies indicate that gabapentinoids are now being recommended, the researchers said. Because cannabinoids, like gabapentinoids, inhibit a certain type of amino acid associated with the disorder, scientists decided to test their therapeutic effectiveness.

The open-label exploratory study, conducted by European researchers at the University of Madrid and published in the Journal of Neurology, found that a cannabis product containing 2.7 mg of THC and 2.5 mg of CBD was “effective in reducing RLS severity” among patients with multiple sclerosis and “associated idiopathic RLS.”

“Improvements were observed after 1 to 3 months of treatment and were maintained after 1 year among patients who continued therapy,” the study of 18 patients with RLS showed. For those who remained in treatment after a year, 67 percent “continued to show sustained improvement.”

The the findings it may not be surprising that cannabis in particular is known to reduce the severity of muscle spasms and related conditions, but its effectiveness for RLS is remarkable given that no state specifically lists it as a condition for medical cannabis.

Of course, RLS can be a symptom of other general disorders like multiple sclerosis, and some states give doctors more latitude to make recommendations for medical marijuana for any condition they see fit.

In any case, research outside of Spain could be based on research into alternative treatment options that could replace dopamine agonists in the treatment of restless legs syndrome.

Marijuana Moment is made possible with the help of readers. If you rely on our pro-cannabis journalism to stay informed, consider a monthly Patreon pledge.

Continue Reading

Cannabis News

Wyoming AG keeps cannabis on Schedule I, rejects federal reclassification

Published

on

By











Wyoming Attorney General Keith Kautz announced on July 7 that he would keep all marijuana products in Schedule I of Wyoming’s Controlled Substances Act, refusing to align the state’s cannabis policy with the federal reorganization order issued earlier this year.

Kautz, who also serves as Wyoming’s drug and substance abuse commissioner, held a public hearing on June 18 after filing an objection to aligning the state’s cannabis schedule with a federal amendment on May 27. State law requires the commissioner to give interested parties an opportunity to be heard after that objection, but only nine people responded. Four email comments supported leaving cannabis as a Schedule I drug, four as Schedule III. It was approved for use and one person attended the hearing to request that cannabis remain in Schedule I.

His decision follows an April 2026 order signed by U.S. Attorney General Todd Blanche that bans state-licensed medical cannabis, FDA-approved cannabis products, cannabis extracts and naturally derived delta-9 THC III.

Kautz’s office says: “After consideration of all stakeholder comments, the commissioner has determined that all marijuana products, including marijuana subject to the state’s medical marijuana license, will remain in Schedule I of the Wyoming Controlled Substances Act.”

His announcement adds, “The decision to reschedule medical marijuana and marijuana products is an important policy decision that is best left to the Wyoming Legislature and should not be made through administrative rule.”

Wyoming remains one of eight states without a medical cannabis program. A December 2020 poll by the University of Wyoming’s Wyoming Center for Polling and Analysis found that 85 percent of state residents support legalizing medical cannabis, despite a failed 2024 ballot initiative effort. Possession of three ounces or less carries up to 12 months in prison under current state law, and selling any amount is punishable by up to 10 years in prison and a $10,000 fine.

Kautz says his office will “properly schedule products approved by the United States Food and Drug Administration once that agency has approved the product,” pointing to the Schedules II and III listings of Cesamet and Dronabinol as evidence that the state complies with federal cannabinoid drug law.










Continue Reading
Advertisement

Trending

Copyright © 2021 The Art of MaryJane Media